Third-line eradication therapy

Toshihiro Nishizawa, Hidekazu Suzuki

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The success rates of Helicobacter pylori eradication treatment may be decreasing in clinical practice, mainly because of the widespread use of antibiotics. Fortunately, the resistance to amoxicillin, tetracycline, and rifabutin has remained low. After the failure of second-line treatment, subsequent treatment should be guided by antimicrobial susceptibility testing whenever possible. With the addition of newer rapid molecular tests to detect H. pylori and the determination of the presence of point mutations, resistance-guided therapy may play a more important role in the future. During empirical third-line therapy, antibiotics used previously should be avoided. Third-line treatment options include fluoroquinolone, rifabutin, tetracycline, furazolidone, and high-dose proton pump inhibitor/amoxicillin therapy. Sitafloxacin shows activities 8–16-fold or greater than those of levofloxacin and could overcome the resistance of H. pylori with gyrA mutations. However, sitafloxacin is not widely available in many countries and has predominantly been employed in Japan. The use of rifabutin should be reserved for the treatment of multiresistant Mycobacterium tuberculosis strains, so that rifabutin is preferably used only as a last resort after amoxicillin, clarithromycin, metronidazole, tetracycline, and fluoroquinolone have failed to eradicate H. pylori.

Original languageEnglish
Title of host publicationHelicobacter Pylori
PublisherSpringer Japan
Pages253-267
Number of pages15
ISBN (Electronic)9784431557050
ISBN (Print)9784431557043
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Rifabutin
Helicobacter pylori
Amoxicillin
Tetracycline
Fluoroquinolones
Therapeutics
Furazolidone
Play Therapy
Anti-Bacterial Agents
Levofloxacin
Clarithromycin
Proton Pump Inhibitors
Metronidazole
Mycobacterium tuberculosis
Point Mutation
Japan
Mutation
sitafloxacin

Keywords

  • Fluoroquinolone
  • Helicobacter pylori
  • Rifabutin
  • Third-line therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Nishizawa, T., & Suzuki, H. (2016). Third-line eradication therapy. In Helicobacter Pylori (pp. 253-267). Springer Japan. https://doi.org/10.1007/978-4-431-55705-0_16

Third-line eradication therapy. / Nishizawa, Toshihiro; Suzuki, Hidekazu.

Helicobacter Pylori. Springer Japan, 2016. p. 253-267.

Research output: Chapter in Book/Report/Conference proceedingChapter

Nishizawa, T & Suzuki, H 2016, Third-line eradication therapy. in Helicobacter Pylori. Springer Japan, pp. 253-267. https://doi.org/10.1007/978-4-431-55705-0_16
Nishizawa T, Suzuki H. Third-line eradication therapy. In Helicobacter Pylori. Springer Japan. 2016. p. 253-267 https://doi.org/10.1007/978-4-431-55705-0_16
Nishizawa, Toshihiro ; Suzuki, Hidekazu. / Third-line eradication therapy. Helicobacter Pylori. Springer Japan, 2016. pp. 253-267
@inbook{e8a414536aad46408ad2d9d1b7675346,
title = "Third-line eradication therapy",
abstract = "The success rates of Helicobacter pylori eradication treatment may be decreasing in clinical practice, mainly because of the widespread use of antibiotics. Fortunately, the resistance to amoxicillin, tetracycline, and rifabutin has remained low. After the failure of second-line treatment, subsequent treatment should be guided by antimicrobial susceptibility testing whenever possible. With the addition of newer rapid molecular tests to detect H. pylori and the determination of the presence of point mutations, resistance-guided therapy may play a more important role in the future. During empirical third-line therapy, antibiotics used previously should be avoided. Third-line treatment options include fluoroquinolone, rifabutin, tetracycline, furazolidone, and high-dose proton pump inhibitor/amoxicillin therapy. Sitafloxacin shows activities 8–16-fold or greater than those of levofloxacin and could overcome the resistance of H. pylori with gyrA mutations. However, sitafloxacin is not widely available in many countries and has predominantly been employed in Japan. The use of rifabutin should be reserved for the treatment of multiresistant Mycobacterium tuberculosis strains, so that rifabutin is preferably used only as a last resort after amoxicillin, clarithromycin, metronidazole, tetracycline, and fluoroquinolone have failed to eradicate H. pylori.",
keywords = "Fluoroquinolone, Helicobacter pylori, Rifabutin, Third-line therapy",
author = "Toshihiro Nishizawa and Hidekazu Suzuki",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-4-431-55705-0_16",
language = "English",
isbn = "9784431557043",
pages = "253--267",
booktitle = "Helicobacter Pylori",
publisher = "Springer Japan",

}

TY - CHAP

T1 - Third-line eradication therapy

AU - Nishizawa, Toshihiro

AU - Suzuki, Hidekazu

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The success rates of Helicobacter pylori eradication treatment may be decreasing in clinical practice, mainly because of the widespread use of antibiotics. Fortunately, the resistance to amoxicillin, tetracycline, and rifabutin has remained low. After the failure of second-line treatment, subsequent treatment should be guided by antimicrobial susceptibility testing whenever possible. With the addition of newer rapid molecular tests to detect H. pylori and the determination of the presence of point mutations, resistance-guided therapy may play a more important role in the future. During empirical third-line therapy, antibiotics used previously should be avoided. Third-line treatment options include fluoroquinolone, rifabutin, tetracycline, furazolidone, and high-dose proton pump inhibitor/amoxicillin therapy. Sitafloxacin shows activities 8–16-fold or greater than those of levofloxacin and could overcome the resistance of H. pylori with gyrA mutations. However, sitafloxacin is not widely available in many countries and has predominantly been employed in Japan. The use of rifabutin should be reserved for the treatment of multiresistant Mycobacterium tuberculosis strains, so that rifabutin is preferably used only as a last resort after amoxicillin, clarithromycin, metronidazole, tetracycline, and fluoroquinolone have failed to eradicate H. pylori.

AB - The success rates of Helicobacter pylori eradication treatment may be decreasing in clinical practice, mainly because of the widespread use of antibiotics. Fortunately, the resistance to amoxicillin, tetracycline, and rifabutin has remained low. After the failure of second-line treatment, subsequent treatment should be guided by antimicrobial susceptibility testing whenever possible. With the addition of newer rapid molecular tests to detect H. pylori and the determination of the presence of point mutations, resistance-guided therapy may play a more important role in the future. During empirical third-line therapy, antibiotics used previously should be avoided. Third-line treatment options include fluoroquinolone, rifabutin, tetracycline, furazolidone, and high-dose proton pump inhibitor/amoxicillin therapy. Sitafloxacin shows activities 8–16-fold or greater than those of levofloxacin and could overcome the resistance of H. pylori with gyrA mutations. However, sitafloxacin is not widely available in many countries and has predominantly been employed in Japan. The use of rifabutin should be reserved for the treatment of multiresistant Mycobacterium tuberculosis strains, so that rifabutin is preferably used only as a last resort after amoxicillin, clarithromycin, metronidazole, tetracycline, and fluoroquinolone have failed to eradicate H. pylori.

KW - Fluoroquinolone

KW - Helicobacter pylori

KW - Rifabutin

KW - Third-line therapy

UR - http://www.scopus.com/inward/record.url?scp=84978274845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978274845&partnerID=8YFLogxK

U2 - 10.1007/978-4-431-55705-0_16

DO - 10.1007/978-4-431-55705-0_16

M3 - Chapter

AN - SCOPUS:84978274845

SN - 9784431557043

SP - 253

EP - 267

BT - Helicobacter Pylori

PB - Springer Japan

ER -